Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Go back to Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 61.12 -0.56 (0.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.68 | 52 Week High | $77.12 | |||
| Open | $61.50 | 52 Week Low | $49.03 | |||
| Day High | $61.81 | P/E | 39.69 | |||
| Day Low | $60.69 | EPS | $1.54 | |||
| Volume | 9,015,491 | |||||



